Lee's Pharmaceutical Holdings (HKSE:00950) Construction In Progress : HK$24 Mil (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Construction In Progress?

Lee's Pharmaceutical Holdings's quarterly construction in progress declined from Dec. 2023 (HK$25 Mil) to Jun. 2024 (HK$0 Mil) but then increased from Jun. 2024 (HK$0 Mil) to Dec. 2024 (HK$24 Mil).

Lee's Pharmaceutical Holdings's annual construction in progress declined from Dec. 2022 (HK$39 Mil) to Dec. 2023 (HK$25 Mil) and declined from Dec. 2023 (HK$25 Mil) to Dec. 2024 (HK$24 Mil).

Lee's Pharmaceutical Holdings Construction In Progress Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Construction In Progress Chart

Lee's Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

52.18

52.57

38.62

24.78

24.18

Lee's Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Construction In Progress	Get a 7-Day Free Trial															38.62	-	24.78	-	24.18

Lee's Pharmaceutical Holdings Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Construction In Progress

Traded in Other Exchanges

N/A

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Executives

Leelalertsuphakun Wanee	2101 Beneficial owner
Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Huang Zuie-chin	2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky	2202 Interest of your spouse
Li Xiaoyi	2101 Beneficial owner
Lee Siu Fong	2101 Beneficial owner
Ubs Group Ag	2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p.	2101 Beneficial owner
Panacea Innovation Limited	2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Apta Finance Sa	2201 Interest of corporation controlled by you
Qualister Sa	2101 Beneficial owner
Paponi Claudia	2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines